ERBB2 and ovarian cancer: Vaccination with HER2 protein (25, 150, and 900 μg) intracellular domain (amino acids 676–1255) with GM-CSF has been found to elicit a sustained (9–12 months) and dose-dependent HER2-specific T-cell-based and antibody-based immunity in a phase I study involving 29 patients bearing stages 2–4 breast and ovarian cancers with high expression of HER2 [208].